CorMedix Stock Hits New 52-Week High On Updated Guidance: The Details

CorMedix Inc CRMD shares are hitting new 52-week highs on Monday after the company raised its sales guidance for the second quarter.

What Happened: CorMedix said one of its Large Dialysis Organization (LDO) customers has started ordering with planned implementation in the second half of 2025.

The company said that implementation of its DefenCath catheter lock solution will initially target at least 50% more patients than previously planned with opportunity for even further expansion.

As a result, CorMedix made adjustments to its agreement with the customer and now expects a modest revenue increase in June with continued growth anticipated in the second half of the year. The company updated its second-quarter net sales guidance from $31 million to a range of $35 million to $40 million to reflect the expected increased use of product by the customer.

“Their implementation of our product will provide access to DefenCath for thousands of adult patients at risk for catheter related bloodstream infections,” said Joseph Todisco, CEO of CorMedix.

D. Boral Capital analyst Jason Kolbert maintained CorMedix with a Buy rating on Monday and reiterated a price target of $15.

How To Buy CRMD Stock

By now you're likely curious about how to participate in the market for Cormedix – be it to purchase shares, or even attempt to bet against the company.

Buying shares is typically done through a brokerage account. You can find a list of possible trading platforms here. Many will allow you to buy “fractional shares,” which allows you to own portions of stock without buying an entire share.

If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to “go short” a share of stock by lending you the shares to sell. The process of shorting a stock can be found at this resource. Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading – either way it allows you to profit off of the share price decline.

CRMD Price Action: CorMedix shares were up 23% at $16.74 at the time of publication Monday, according to Benzinga Pro. CorMedix has traded as low as $3.61 over the past year. The stock is up approximately 111% on a year-to-date basis.

Read Next:

• This Ventas Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday
• Hims & Hers Health Stock Is Tumbling Monday: What’s Happening?

Photo: MacroEcon/Shutterstock.